NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
Clinical Trials
4 trialsNCT02500927 2024-11-20
A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
Astellas Pharma Inc
Phase 2 Terminated
NCT03082300 2024-11-20
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Inc
Phase 1 Terminated
NCT02192697 2024-11-14
An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Inc
Phase 1/2 Terminated